Answers are grounded in this paper and cite their sources.
The design, synthesis, and biological characterization of an orally active prodrug (3) of gemcitabine are described. Additionally, the identification of a novel co-crystal solid form of the compound is presented. Valproate amide 3 is orally bioavailable and releases gemcitabine into the systemic circulation after passing through the intestinal mucosa. The compound has entered clinical trials and is being evaluated as a potential new anticancer agent.
No takes yet. Share an insight, caveat, or question.
Bender et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: